Beta Drugs Limited has informed the Exchange regarding Board meeting held on January 09, 2026.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited's board, at its meeting on January 9, 2026, approved acquiring a 66.09% stake in Nivian Life Sciences Private Limited, an IVF pharmaceutical marketing company, for a total consideration of INR 69.39 Crores. The deal is structured as a mix of cash (INR 20.82 Crores for 3,28,360 shares) and a share swap (INR 48.58 Crores for 10,94,535 shares). Under the swap, the company will issue 2,83,668 equity shares at INR 1,712.49 each to 33 selling shareholders of Nivian. The target reported FY25 turnover of INR 29.12 Crores and EBITDA of INR 4.22 Crores. The board also approved the ESOP 2026 scheme covering up to 2,00,000 stock options, an increase in authorised share capital from INR 11 Crore to INR 11.40 Crore, and an EGM on February 4, 2026 to seek shareholder approval.
This acquisition gives Beta Drugs a foothold in the fast-growing IVF pharmaceutical segment, leveraging distribution synergies with its existing oncology business. Existing shareholders will face dilution from the 2,83,668 new shares issued as consideration, while the company also needs to fund the INR 20.82 Crore cash component. The deal is not a related party transaction and is expected to complete within 3 months.